Company intelligence / Profile preview

ACT225 BioTherapeutics Corporation

Quebec City, Quebec, Canada

Ownership: Private
Development stage: Other

Overview

Preclinically validated actinium-225 anti-EGFR antibody drug radioconjugate with zirconium-89 imaging pair; advancing to GMP production and clinical trial-enabling studies for potential Phase 1 trial

Therapeutic areas: Oncology
Modalities: Antibody-drug conjugateRadiopharmaceutical
Industry: Biotech

Beyond the preview

Go deeper on ACT225 BioTherapeutics Corporation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ACT225 BioTherapeutics Corporation.

Explore the full profile